← Eichor
Condition: Poly Adp Ribose Polymerase Inhibitors Synced from ClinicalTrials.gov · July 29, 2026

Recruiting studies: Poly Adp Ribose Polymerase Inhibitors

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Fluzoparib Combined With Bevacizumab in PSROC Previously Treated With PARPi
Phase 2 · 1 location(s) · Chongqing University Cancer Hospital · NCT05551208Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma
Phase 1/Phase 2 · 10 location(s) · St. Jude Children's Research Hospital · NCT04901702Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 · 18 location(s) · MOMA Therapeutics · NCT06545942Niraparib Monotherapy as Maintain and Recurrent Treatment of Endometrial Serous Carcinoma
Phase 2 · 1 location(s) · Shandong University · NCT04716686Genetic Landscape in Women with Metastatic Ovarian Cancer Before and During Treatment with PARP Inhibitors
NA · 1 location(s) · European Institute of Oncology · NCT06785077Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Mai
Phase 2 · 1 location(s) · Korea University Guro Hospital · NCT05704621PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05759546Testing the Combination of the Anti-cancer Drugs ZEN003694 (ZEN-3694) and Talazoparib in Patients With Advanced Solid Tu
Phase 2 · 36 location(s) · National Cancer Institute (NCI) · NCT05327010ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
Phase 2 · 1 location(s) · Alexander B Olawaiye, MD · NCT05071937Circulating Tumor DNA (ctDNA) Monitoring in the Assessment and Prediction of the Efficacy of PARP Inhibitors (PARPi)
Phase N/A · 1 location(s) · Sun Yat-sen University · NCT05116579Olaparib+Trastuzumab+Pertuzumab Neoadjuvant for Elderly HER2+ Breast Cancer
Phase 4 · 1 location(s) · Wen-Ming Cao · NCT07695259Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
Phase 1 · 9 location(s) · Norman J. Lacayo · NCT05101551PARP Inhibitor With 177Lu-DOTA-Octreotate PRRT in Patients With Neuroendocrine Tumours
Phase 1 · 1 location(s) · Peter MacCallum Cancer Centre, Australia · NCT05053854Safety Assessment of Concurrent Radiotherapy and Novel Systemic Therapy for Breast Cancer
NA · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT06197581Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treat
Phase 1/Phase 2 · 1 location(s) · Fundación de investigación HM · NCT06607692ARON-3 Study: International Multicentric Retrospective Study to Collect Global Experiences in the Treatment of Patients
Phase N/A · 1 location(s) · Hospital of Macerata · NCT06200558Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma
Phase 1/Phase 2 · 1 location(s) · Jun Guo · NCT05983237Phase II Trial of the PARP Inhibitor Niraparib and PD-1 Inhibitor Dostarlimab in Patients With Advanced Cancers With Act
Phase 2 · 1 location(s) · M.D. Anderson Cancer Center · NCT05700721Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Phase 1/Phase 2 · 12 location(s) · Artios Pharma Ltd · NCT05898399CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer
Phase 1 · 1 location(s) · Lan Coffman · NCT05942300Collection of Endometrial Cancer-derived Organoids to Evaluate the Efficacy of PARP Inhibitors: PENDOR Pilot Study
Phase N/A · 1 location(s) · Centre Francois Baclesse · NCT06603506Investigating Idetrexed and Olaparib in Patients With Ovarian Cancer
Phase 1 · 3 location(s) · Institute of Cancer Research, United Kingdom · NCT06976892Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
Phase 2 · 1 location(s) · Ronald Buckanovich · NCT05538091SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Phase 2 · 7 location(s) · Institute of Cancer Research, United Kingdom · NCT05990192Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer
Phase 1 · 5 location(s) · Nerviano Medical Sciences · NCT06930755Trastzumab Deruxtecan Versus SOC in Recurrent Ovarian That Progressed on Prior PARP Inhibitor Therapy
Phase 2 · 1 location(s) · Yonsei University · NCT07340164FTT PET/CT in Metastatic Prostate Cancer
Phase N/A · 1 location(s) · Abramson Cancer Center at Penn Medicine · NCT05242744A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abirater
Phase 2 · 7 location(s) · Prostate Cancer Clinical Trials Consortium · NCT06844383Study of NMS-03305293 in Adult Patient With Relapsed Small Cell Lung Cancer
Phase 1 · 3 location(s) · Nerviano Medical Sciences · NCT06931626
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.